Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference
Stereotaxis (NYSE: STXS) will participate in the Piper Sandler 37th Annual Healthcare Conference. David Fischel, chairman and CEO, will join a fireside discussion on December 3, 2025 at 9:00 AM ET and will be available for one-on-one investor meetings that day.
The release notes the company is achieving key regulatory milestones and showing early commercial growth. Stereotaxis develops robotic systems for minimally invasive endovascular intervention and reports its technology has been used to treat over 150,000 patients. The company included standard forward-looking risk disclosures about regulatory timing, market acceptance, and other business risks.
Stereotaxis (NYSE: STXS) parteciperà alla Piper Sandler 37ª Conferenza Annuale sull'Healthcare. David Fischel, presidente e CEO, parteciperà a una discussione informale il 3 dicembre 2025 alle 9:00 ET e sarà disponibile per incontri individuali con gli investitori quel giorno.
Il comunicato evidenzia che l'azienda sta raggiungendo traguardi normativi chiave e mostra una crescita commerciale iniziale. Stereotaxis sviluppa sistemi robotici per interventi endovascolari minimamente invasivi e segnala che la sua tecnologia è stata utilizzata per trattare oltre 150.000 pazienti. L'azienda ha incluso consueti avvisi di rischio prospettico riguardo ai tempi regolatori, all'accettazione del mercato e ad altri rischi aziendali.
Stereotaxis (NYSE: STXS) participará en la 37ª Conferencia Anual de Healthcare de Piper Sandler. David Fischel, presidente y CEO, participará en una charla junto al fuego el 3 de diciembre de 2025 a las 9:00 AM ET y estará disponible para reuniones individuales con inversionistas ese día.
El comunicado señala que la empresa está logrando hitos regulatorios clave y mostrando un crecimiento comercial temprano. Stereotaxis desarrolla sistemas robóticos para intervenciones endovasculares mínimamente invasivas y reporta que su tecnología ha sido utilizada para tratar a más de 150,000 pacientes. La empresa incluyó avisos estándar de riesgo prospectivo sobre el tiempo regulatorio, la aceptación del mercado y otros riesgos comerciales.
Stereotaxis (NYSE: STXS) 는 Piper Sandler 37회 연례 헬스케어 컨퍼런스에 참여합니다. David Fischel 회장 겸 CEO는 2025년 12월 3일 동부 표준시 9:00에 열리는 화롯대 토론에 참여하고 그 날 일대일 투자자 미팅도 사용할 수 있습니다.
보도자료에 따르면 회사는 주요 규제 이정표를 달성하고 초기 상업적 성장을 보이고 있습니다. Stereotaxis는 최소 침습적 혈관 내 시술을 위한 로봇 시스템을 개발하며, 이 기술이 150,000명 이상의 환자를 치료하는 데 사용되었다고 보고합니다. 회사는 규제 시점, 시장 수용성 및 기타 비즈니스 위험에 대한 표준적 미래 위험 공시를 포함했습니다.
Stereotaxis (NYSE: STXS) participera à la 37e Conférence annuelle sur les soins de santé de Piper Sandler. David Fischel, président et PDG, participera à une discussion informelle le 3 décembre 2025 à 9h00 ET et sera disponible pour des réunions investisseurs en tête-à-tête ce jour-là.
Le communiqué indique que l'entreprise atteint des étapes réglementaires clés et montre une croissance commerciale précoce. Stereotaxis développe des systèmes robotiques pour des interventions endovasculaires mini-invasives et indique que sa technologie a été utilisée pour traiter plus de 150 000 patients. L'entreprise a inclus des avertissements standard concernant les risques prospectifs liés au calendrier réglementaire, à l'acceptation du marché et à d'autres risques commerciaux.
Stereotaxis (NYSE: STXS) wird an der Piper Sandler 37. jährlichen Healthcare-Konferenz teilnehmen. David Fischel, Vorsitzender und CEO, wird an einer Fireside-Diskussion am 3. Dezember 2025 um 9:00 Uhr ET teilnehmen und an diesem Tag für Einzelgespräche mit Investoren zur Verfügung stehen.
Die Pressemitteilung hebt hervor, dass das Unternehmen wesentliche regulatorische Meilensteine erreicht und ein frühes kommerzielles Wachstum zeigt. Stereotaxis entwickelt robotergestützte Systeme für minimalinvasive endovasculare Eingriffe und meldet, dass die Technologie zur Behandlung von über 150.000 Patienten eingesetzt wurde. Das Unternehmen hat standardmäßige zukunftsgerichtete Offenlegungen zu regulatorischem Zeitplan, Marktakzeptanz und anderen Geschäftsrisiken eingefügt.
Stereotaxis (NYSE: STXS) ستشارك في المؤتمر السنوي السابع والثلاثين للرعاية الصحية لبايبر ساندلر. سيشارك ديفيد فيشل، رئيس مجلس الإدارة والرئيس التنفيذي، في مناقشة حول الموقد في 3 ديسمبر 2025 الساعة 9:00 صباحاً بتوقيت شرق الولايات المتحدة وسيتاح له عقد اجتماعات فردية مع المستثمرين في ذلك اليوم.
تشير البيان الصحفي إلى أن الشركة تحقق معالم تنظيمية رئيسية وتظهر نمواً تجارياً مبكراً. تطور Stereotaxis أنظمة روبوتية لإجراءات داخل الأوعية الدموية طفيفة التوغل وتذكر أن تقنيتها قد استُخدمت لعلاج أكثر من مئة وخمسين ألف مريض. كما أدرجت الشركة إفصاحات مخاطر مستقبلية معيارية بشأن التوقيت التنظيمي وقبول السوق وغيرها من مخاطر الأعمال.
- None.
- None.
ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference.
David Fischel, Stereotaxis Chairman and CEO, is scheduled to participate in a fireside discussion on Wednesday, December 3rd, 2025, at 9:00 am Eastern Standard Time and will be available that same day for one-on-one meetings.
“This is an exciting period for Stereotaxis as we achieve key regulatory milestones and demonstrate early commercial growth," said Mr. Fischel. "We look forward to engaging with investors at the Piper Sandler conference."
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, including statements regarding the completion of the Company’s offering and the anticipated use of proceeds therefrom, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. There can be no assurance that the Company will recognize revenue related to customer purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
When will Stereotaxis (STXS) present at the Piper Sandler Healthcare Conference?
Who from Stereotaxis (STXS) will speak at the December 3, 2025 conference?
Will Stereotaxis (STXS) hold investor meetings at Piper Sandler on December 3, 2025?
What commercial progress did Stereotaxis (STXS) cite ahead of the Piper Sandler conference?
How many patients have been treated with Stereotaxis technology as disclosed in the release?
Does the Stereotaxis (STXS) press release include forward-looking risk warnings?
